4xTBLhfLn/JdGMddJP7cC8yIXNOVsvR7z++RPF/BJCYsuWGQA0amhsZSItcH5KUjLWk5Br/PibXcr5oUR6+NenILBZ4KcS1Im5T
AZA口服制剂CC-486在AML和MDS患者 ASCT后维持治疗中显示有良好的耐受性[54],且便于剂量调整和坚持治疗。目前CC-486正被评估作为未经治疗AML患者强化疗后的维持治疗(QUAZAR
2LVx8c2t7SybXuWHj+tN+OcULXAMd0XD799v80EvqH3EY++vfu2b9/+23vu3bNnj2s7AGBAKc10dO7bt2/c0cc0NTUl+j7nytl
WsZn7LliH3V6Cc/iUFZHC2H1CKlUqtpYWvsqnJIrI0zd+/+pbBXO4FZEpJMeBUnlOpoCCFrC5/+/RfwAq8Z/HZghdH
3a5PioLr31ds1ZdLnefW+fUlq8yT7VhyQAsBtMJqvCOu3cc1IXLs3G+L9PwZH+Ki88xQ3L3xleS8vPVdq4XIK2uAVxn2nD++l